Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Androgen Deprivation Therapy (ADT) Clear all
Completed Phase 3 Interventional

The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

NCT00171639
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Tucson, Arizona • Long Beach, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

NCT05361798
View directory record Official record
Conditions
Cancer Of Prostate
Interventions
PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

NCT07364071
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Radiation therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

NCT01615120
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 125 mg, GTx-758 250 mg
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
26
States / cities
Burbank, California • Los Angeles, California • San Bernardino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 13, 2026, 9:46 PM EDT
Active, not recruiting Early Phase 1 Interventional

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

NCT03511196
View directory record Official record
Conditions
Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Adaptive Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 13, 2026, 9:46 PM EDT
Completed No phase listed Observational

Physical Function During ARSI Treatment

NCT05612880
View directory record Official record
Conditions
Advanced Prostate Carcinoma
Interventions
androgen receptor signaling inhibitors
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional

Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

NCT03654638
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Dietary Intervention, Questionnaire Administration
Combination Product · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 13, 2026, 9:46 PM EDT
Completed No phase listed Observational

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

NCT02003417
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • High Point, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Phase 2Phase 3 Interventional

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT04787744
View directory record Official record
Conditions
Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer
Procedure · Radiation · Other + 1 more
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
20
States / cities
Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Withdrawn Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003517
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
Interventions
antineoplaston A10, antineoplaston AS2-1, bicalutamide, flutamide, leuprolide acetate, alternative product therapy, antiandrogen therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy, endocrine therapy, hormone therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 13, 2026, 9:46 PM EDT
Terminated Phase 2 Interventional Results available

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

NCT02582749
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions
LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
Drug · Radiation
Lead sponsor
Ajjai Alva, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Early Phase 1 Interventional

Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy

NCT03661437
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Actigraph, Questionnaire Administration, Systematic Light Exposure
Device · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

NCT00589472
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Phase 2 Interventional

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

NCT06972875
View directory record Official record
Conditions
Prostate CA, Androgen Deprivation Therapy
Interventions
Fezolinetant
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 1 Interventional

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

NCT02458716
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Prostate Carcinoma Metastatic to the Bone
Interventions
Robotic Assisted Radical Prostatectomy, Conventional open retropubic radical prostectomy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Procedure · Other · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Duarte, California • Orange, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 4 Interventional Results available

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

NCT00470834
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
dutasteride, placebo, bicalutamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 90 Years · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
47
States / cities
Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 2 Interventional Results available

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT01120236
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Bicalutamide, Cixutumumab, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Pharmacological Study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
169
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 13, 2026, 9:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

NCT04737109
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer
Interventions
Ipatasertib, Darolutamide, Androgen Deprivation Therapy
Drug
Lead sponsor
David VanderWeele
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 13, 2026, 9:46 PM EDT
Completed No phase listed Observational

Micro RNAs to Predict Response to Androgen Deprivation Therapy

NCT02366494
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 13, 2026, 9:46 PM EDT
Recruiting Not applicable Interventional

Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy

NCT07594002
View directory record Official record
Conditions
Accupuncture, Prostate Cancer, Hormone Therapy, Hot Flashes
Interventions
Real Acupuncture, Sham Acupuncture
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Completed Phase 3 Interventional Results available

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapy, docetaxel
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
343
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 13, 2026, 9:46 PM EDT
Not yet recruiting Phase 2 Interventional

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Active, not recruiting Not applicable Interventional

Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer

NCT02722525
View directory record Official record
Conditions
Cardiovascular Injury, Prostate Carcinoma
Interventions
Magnetic Resonance Imaging, Exercise Intervention, Perfusion Magnetic Resonance Imaging, Spectroscopy, Laboratory Biomarker Analysis
Procedure · Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 13, 2026, 9:46 PM EDT
Terminated Phase 2 Interventional Results available

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

NCT00937768
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 13, 2026, 9:46 PM EDT